Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FKC
|
|||
| Former ID |
DIB006653
|
|||
| Drug Name |
Eltoprazine
|
|||
| Synonyms |
Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 3 | [1] | |
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1], [2] | ||
| Dyskinesia [ICD-11: MB47.4] | Phase 2 | [3] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5] | Phase 2 | [4] | ||
| Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 2 | [2] | ||
| Company |
Amarantus bioscience; psychogenics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H16N2O2
|
|||
| Canonical SMILES |
C1CN(CCN1)C2=C3C(=CC=C2)OCCO3
|
|||
| InChI |
1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2
|
|||
| InChIKey |
WVLHGCRWEHCIOT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 98224-03-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Agonist | [5] |
| 5-HT 1B receptor (HTR1B) | Target Info | Agonist | [5], [6] | |
| 5-HT 2C receptor (HTR2C) | Target Info | Antagonist | [5] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Calcium signaling pathway | ||||
| Gap junction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT01266174) Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults. U.S. National Institutes of Health. | |||
| REF 5 | Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. | |||
| REF 6 | Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.